Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.79 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.44 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.44 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 0.44 |
| ▸ | PRKACA | P17612 | 1/20 | 0.44 |
| ▸ | GSK3A | P49840 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | IRAK1 | P51617 | 1/20 | 0.44 |
| ▸ | PRKX | P51817 | 1/20 | 0.44 |
| ▸ | PRKG1 | Q13976 | 1/20 | 0.44 |
| ▸ | PKN2 | Q16513 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10433409 | 1.00 | EPHX1 (0.79) | EPHX1KMT2AMEN1TAAR1MAPK1 | |
| SCHEMBL2703617 | 1.00 | EPHX1 (0.79) | EPHX1KMT2AMEN1TAAR1MAPK1 | |
| SCHEMBL11043354 | 0.92 | EPHX1 (0.67) | EPHX1KMT2AMEN1TAAR1MAPK1 | |
| SCHEMBL29257172 | 0.88 | EPHX1 (1.00) | EPHX1KMT2AMEN1TAAR1MAPK1 | |
| SCHEMBL12681300 | 0.81 | EPHX1 (0.79) | EPHX1KMT2AMEN1TAAR1SLC6A4 | |
| SCHEMBL7509446 | 0.81 | EPHX1 (0.79) | EPHX1KMT2AMEN1TAAR1MAPK1 | |
| SCHEMBL29800395 | 0.81 | EPHX1 (0.71) | EPHX1KMT2AMEN1TAAR1SLC6A4 | |
| SCHEMBL7348151 | 0.80 | MAPK1 (0.58) | EPHX1KMT2AMEN1MAPK1CYP3A4 | |
| SCHEMBL7345520 | 0.80 | MAPK1 (0.58) | EPHX1KMT2AMEN1MAPK1CYP3A4 | |
| SCHEMBL6316970 | 0.79 | EPHX1 (0.73) | EPHX1KMT2AMEN1TAAR1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7553850-B2 | Tricyclic-bridged piperidinylidene derivatives as δ-opioid modulators | JANSSEN PHARMACEUTICA NV (BG) | 2009-06-30 | — | — | US | claimed |
| US-20060030585-A1 | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-02-09 | — | — | US | claimed |
| US-20090291979-A1 | TRICYCLIC-BRIDGED PIPERIDINYLIDENE DERIVATIVES AS DELTA OPIOID MODULATORS | DAX SCOTT | 2009-11-26 | — | — | US | disclosed |
| US-7553850-B2 | Tricyclic-bridged piperidinylidene derivatives as δ-opioid modulators | JANSSEN PHARMACEUTICA NV (BG) | 2009-06-30 | — | — | US | disclosed |
| US-20060030585-A1 | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090291979-A1 | TRICYCLIC-BRIDGED PIPERIDINYLIDENE DERIVATIVES AS DELTA OPIOID MODULATORS | OPRD1, OPRK1, OPRM1 | EPHX1 1853/4885KMT2A 2219/4885MEN1 4880/4885 |
| US-20060030585-A1 | Tricyclic delta-opioid modulators | OPRD1, OPRK1, OPRL1 | EPHX1 2079/4885KMT2A 2064/4885MEN1 4869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.